file:: [khanna-puneet-utility-of-high-flow-nasal-oxygen-in_1681832191732_0.pdf](../assets/khanna-puneet-utility-of-high-flow-nasal-oxygen-in_1681832191732_0.pdf)
file-path:: ../assets/khanna-puneet-utility-of-high-flow-nasal-oxygen-in_1681832191732_0.pdf

- one longitudinal study
  ls-type:: annotation
  hl-page:: 1
  hl-color:: yellow
  id:: 643eb921-3a55-455a-baad-2b255fd7d3be
- lesser incidence of desaturation spells (odds ratio [OR] = 0.23; 95% CI 0.11–0.48; I2 = 71%), reduced procedural interruption (OR = 0.11; 95% CI 0.02–0.60; I2 = 88%), better nadir SpO 2 level during procedure (mean difference [MD] = 3.16; 95% CI 0.54–5.78; I2 = 73%), overall lesser incidence of sedation-related adverse events (OR = 0.63;95% CI 0.42–0.93; I2 = 25%), with no significant impact on the duration of endoscopy (MD = 0.15; 95% CI − 0.02 to 0.31, I2 = 0%).
  ls-type:: annotation
  hl-page:: 1
  hl-color:: red
  id:: 643eb942-5c40-4d13-80cf-ce2067c86999
- Patients receiving HFNO under sedation had a lesser risk of desaturation in comparison to patients with low-flow oxygen delivery devices
  ls-type:: annotation
  hl-page:: 3
  hl-color:: yellow
  id:: 643eb99b-02c1-4cfe-99d1-6d145496c77a
- The application of HFNO with sedation during upper GI endoscopic procedures had a lower risk of interruption in between than low-flow oxygen delivery devices
  ls-type:: annotation
  hl-page:: 4
  hl-color:: yellow
  id:: 643eb9bd-c673-4e5b-92b9-36ab03e5b6ad
- No significant alteration in the overall duration of endoscopic procedures was found
  ls-type:: annotation
  hl-page:: 4
  hl-color:: yellow
  id:: 643eb9d4-58ff-4e4f-bb34-c2cc5473656d
- HFNO was associated with a reduced risk of adverse events in comparison to patients with low-flow oxygen delivery devices
  ls-type:: annotation
  hl-page:: 4
  hl-color:: yellow
  id:: 643eb9f7-2bb4-4687-9620-53c0964ef184
- The patients with HFNO showed significantly elevated nadir lowest SpO 2 than patients with low-flow oxygen delivery devices
  ls-type:: annotation
  hl-page:: 4
  hl-color:: yellow
  id:: 643eba19-18b5-4d1c-9f8a-b756dff6ef58
- No significant difference in overall propofol consumption
  ls-type:: annotation
  hl-page:: 6
  hl-color:: yellow
  id:: 643eba42-f20b-4d73-90f6-a0eb86649c62